Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
2023年11月6日 - 10:01PM
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage
immuno-oncology company developing therapies to improve patient
lives and increase survival, today announced the presentations of
updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2
(IMM60), an invariant natural killer T cell (iNKT) engager for
patients with NSCLC and advanced melanoma, and its ADPORT-601
adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7
(A2B inhibitor) in multiple solid tumors at SITC.
The patient data from IMPORT-201, a multi-arm Phase 1/2 trial
evaluating PORT-2 in multiple settings, included front-line and
refractory NSCLC, and refractory melanoma, as a monotherapy and in
combination with Merck’s anti-PD-1 therapy, KEYTRUDA®
(pembrolizumab). These data build on previous results shared at the
2023 American Society of Clinical Oncology (ASCO) meeting in June
and include new information on the novel pharmacology profile of
PORT-2.
“We are encouraged by the expanding patient data set that
supports results showing PORT-2 having a favorable safety and
tolerability profile as a monotherapy as well as early combination
data,” said Dr. Ian Walters, Chief Executive Officer of Portage
Biotech. “We continue to see single agent activity of PORT-2 at the
3 and 9 mg/m2 dose. We are looking forward to exploring higher dose
levels as monotherapy and in combination."
Dr. Sumit K. Subudhi from the University of Texas MD Anderson
Cancer Center presented the design of the ADPORT-601 trial. This
trial will evaluate a potent and selective A2A inhibitor (PORT-6),
and an A2B inhibitor (PORT-7), alone and in combination with other
immunotherapies specifically in tumors that overexpress adenosine.
This trial is being conducted in collaboration with Merck and is
being designed to explore A2A + pembrolizumab, A2B + pembrolizumab,
and the triplet of A2A + A2B (both at the optimal biologic dose) +
pembrolizumab. Dr. Subudhi commented, “Portage’s potentially
best-in-class A2A and A2B compounds coupled with a keen focus on
patient selection and translational endpoints make this trial very
appealing. I especially appreciate Portage’s proactive approach to
understanding the immune effects of modulating the adenosine
pathway early in their development program.”
SITC presentations are available now to registrants through the
conference platform. Both posters will be added to the
“Presentations & Publications” section of Portage’s website
following the conference.
Presentation Details:Abstract
Title: ADPORT-601 (TT-10-101): First-in-Human Study of
Adenosine 2A (A2A) and Adenosine 2B (A2B) receptor antagonists
in Participants with Selected Advanced Solid
TumorsPresenter/First Author: Sumit K. Subudhi,
University of Texas MD Anderson Cancer CenterAbstract
Number: 759
Abstract Title: IMP-MEL: A phase 1
first-in-human dose-finding study of a novel invariant natural
killer T-cell agonist (iNKT) IMM60 in advanced melanoma and
non-small-cell lung cancer
(NSCLC) Presenter/First
Author: Nicholas Coupe, MBBS, Oxford University Hospital,
Oxford, United KingdomAbstract Number: 712
About IMPORT-201The IMPORT-201 trial is a
multicenter multi-arm Phase 1/2 trial evaluating PORT-2 (IMM60) in
metastatic non-small cell lung cancer and advanced melanoma. The
Phase 1 portion of the trial seeks to establish the recommended
Phase 2 dose of PORT-2 alone or in combination with pembrolizumab.
To learn more about the study, visit
clinicaltrials.gov.
About ADPORT-601The ADPORT-601 adaptive Phase
1a/1b study will explore Portage Biotech’s small molecule adenosine
antagonists, PORT-6 and PORT-7, as monotherapies, in combination
with one another and potentially in combination with other Portage
assets. Phase 1a will evaluate the safety of PORT-6 and PORT-7 both
as a monotherapy and in combination with immune checkpoint
inhibitors, with the goal of identifying a recommended Phase 2
dose. Phase 1b is designed to explore PORT-6 and PORT-7
monotherapies in an enriched population and in randomized trials
versus standard of care. To learn more about the study, visit
clinicaltrials.gov.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
About Portage Biotech Inc.Portage is a
clinical-stage immuno-oncology company advancing multi-targeted
therapies to extend survival and significantly improve the lives of
patients with cancer. Lead programs in the Portage portfolio
include first-in-class invariant natural killer T cell (iNKT) small
molecule engagers and potentially best-in-class adenosine
antagonists. These programs are being advanced using innovative
trial designs and translational data to identify the patient
populations most likely to benefit from treatment. The Company’s
unique business model leverages a strong network of academic
experts and large pharma partners to rapidly and efficiently
advance multiple products. For more information, please visit
www.portagebiotech.com, follow us on Twitter at @PortageBiotech or
find us on LinkedIn at Portage Biotech Inc.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things, the Company's
belief that targeting the adenosine pathway could improve outcomes
in multiple cancer types; the Company's belief that PORT-6 is more
potent, durable and selective than other agents; the Company's
commitment to advancing the PORT-6 program along with its ongoing
development of its iNKT agonist; the Company's plan to evaluate
PORT-7 as part of the ADPORT Phase 1a/1b trial; the Company's
expectation that PORT-7 will allow for customization of treatment
for any given tumor type to identify patients that are likely to
respond and have potential to benefit most from treatment; the
expectation that the PORT-6 A2AR inhibitor and PORT-7 A2BR
inhibitor trial will provide insight into understanding of the
therapeutic implications of targeting each pathway alone or in
combination at optimum biologic doses in multiple cancer types; the
ability of the Company’s clinical trials to provide insights into
potentially improving patient selection strategies by selecting
patients whose tumors have a high level of adenosine expression;
and the expected benefits of adenosine and its potential impact on
the future of cancer treatment. As a result, forward-looking
statements are subject to certain risks and uncertainties,
including, but not limited to: the Company’s plans and ability to
develop and commercialize its product candidates and the timing of
its development programs; the Company’s clinical development of its
product candidates, including the results of current and future
clinical trials; the benefits and risks of the Company’s product
candidates as compared to others; the Company’s maintenance and
establishment of intellectual property rights in its product
candidates; the Company’s need for financing and its estimates
regarding its capital requirements and future revenues and
profitability; the Company’s estimates of the size of the potential
markets for its product candidates; its selection and licensing of
product candidates; and other factors set forth in “Item 3 - Key
Information - Risk Factors” in the Company’s Annual Report on Form
20-F for the year ended March 31, 2023. Although the Company
believes that the expectations reflected in these forward-looking
statements are reasonable, undue reliance should not be placed on
them as actual results may differ materially from these
forward-looking statements. The forward-looking statements
contained in this press release are made as of the date hereof, and
the Company undertakes no obligation to update publicly or revise
any forward-looking statements or information, except as required
by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:ir@portagebiotech.com
Media Relations:media@portagebiotech.com
Portage Biotech (NASDAQ:PRTG)
過去 株価チャート
から 8 2024 まで 9 2024
Portage Biotech (NASDAQ:PRTG)
過去 株価チャート
から 9 2023 まで 9 2024